Form 8-K Insight Molecular Diagno For: Feb 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St to open higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Insight Molecular Diagnostics partners with Quest Diagnostics for specimen collection services
February 26, 2026 4:41 PM ESTInsight Molecular Diagnostics Inc. (NASDAQ: IMDX) entered into a specimen collection agreement with Quest Diagnostics Incorporated on February 20, 2026, according to a company statement.
Under the agreement, Quest Diagnostics will provide specimen collection services for samples that will undergo the GraftAssureCore test. The blood... More
